Logo

Artemis Will Make Knock-outs For Merck

Jun 10, 2002

NEW YORK, June 10-Exelixis subsidiary Artemis Pharmaceuticals has struck a deal with Merck to create customized mouse models of disease, the company said today.

 

Merck will provide genetic specifications for the mice, and Artemis will use its gene inactivation technology to develop the strains.

 

The companies did not disclose financial details of the agreement.

 

Exelixis acquired Cologne, Germany-based Artemis in 2001.

 

For more details, see the company website.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.